MOESSNER, Ekkehard,STUBENRAUCH, Kay-Gunnar,DAROWSKI, Diana,KLEIN, Christian
申请号：
CR20190440
公开号：
CR20190440A
申请日:
2018.03.26
申请国别(地区):
CR
年份:
2019
代理人:
摘要：
The current invention generally refers to the antigen alliance receiver which can specifically combine with the mutated Fc domain and the T cell represented by the antigen alliance receiver. More precisely, the present invention refers to T-cells, which are produced by transfusion / transformation of antigen alliance receptors attracted by specific binding / interaction in the field of therapeutic antibody mutation FC. In addition, the invention refers to a kit containing T cells and / or nucleic acid molecules of the invention,Vectors represent antigen binding receptors and one or more tumor target antibodies, including mutated FC domains. The invention also provides the production and use of T cells and specific tumor antibodies in methods for treating specific diseases, as well as synthetic drugs / drugs including T cells and / or therapeutic antibodies,In this case, T cells must be managed in combination with one or more antigens and therapeutic tumor targets, including Fc domain of one variant, whose alliance is reduced to Fc receptor. In general, in this case, the specific binding recipient can be associated with Fc receptor of variant a.and t cells expressing these antien binding receptors. More precisely, the application protocol with an engineer FC receiver includes a CD3 intracellular domain that can be used for CD28 internal and transmembrane domains. The extracellular part preferably consistes of an anti pro329gly antioody variable domain. For cancer treatment and diagnosisLa presente invención se refiere de manera general a receptores de unión a antígeno capaces de unión específica a dominios Fc mutados con unión a receptor Fc reducida y células T que expresan dichos receptores de unión a antígeno. Más exactamente, la presente invención se refiere a células T, transfectadas/transducidas con un receptor de unión a antígeno que resulta atraído por la unión/interacción específica con el dominio Fc mutado de anticuerpos terapéuticos. Además, la invención se
